rs35219372

This is a synonymous variant in the ARVCF gene — it does not change the protein's amino acid sequence.

Research that mentions this SNP (1)

A functional variant provided further evidence for the association of ARVCF with schizophrenia
AssociationN=828Sergi Mas et al.(2010)· American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

A case-control association study identifying rs165815, a nonsynonymous SNP in ARVCF exon 19 (Q906R), associated with schizophrenia risk in a Spanish population. The C allele showed increased risk with OR=3.39 (p=0.02) for homozygotes and OR=1.63 overall (p=0.007). The association was confirmed in an independent replication sample. Total sample: 344 schizophrenia cases and 484 controls.

Traits studied:Acute psychotic disorderDelusional disorderSchizoaffective disorderSchizophreniaSchizotypal disorder

About ARVCF

Armadillo Repeat gene deleted in Velo-Cardio-Facial syndrome (ARVCF) is a member of the catenin family. This family plays an important role in the formation of adherens junction complexes, which are thought to facilitate communication between the inside and outside environments of a cell. The ARVCF gene was isolated in the search for the genetic defect responsible for the autosomal dominant Velo-Cardio-Facial syndrome (VCFS), a relatively common human disorder with phenotypic features including cleft palate, conotruncal heart defects and facial dysmorphology. The ARVCF gene encodes a protein containing two motifs, a coiled coil domain in the N-terminus and a 10 armadillo repeat sequence in the midregion. Since these sequences can facilitate protein-protein interactions ARVCF is thought to function in a protein complex. In addition, ARVCF contains a predicted nuclear-targeting sequence suggesting that it may have a function as a nuclear protein. [provided by RefSeq, Jun 2010]

View all ARVCF variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…